KELOWNA, BC / ACCESSWIRE / December 19, 2016 / Marapharm Ventures Inc., ("Marapharm") (OTCQB: MRPHF) of Kelowna, British Columbia, announces that it's modifying its farming model to include some farming styles which originated from conventional vertical farming, which is the practice of producing food in vertically stacked layers, like a skyscraper within high ceilinged buildings. Marapharm's farming model is called "vertical plus."
"While farming in a vertical dimension, every cubic inch contributes to the final yield of flower, as opposed to the more conventional linear oriented marijuana gardens, which are really taking more of a square foot approach. The difference is that a whole other dimension is being contributed to the total harvest. Effectively, the cultivation space increases by several times and of course, then, the product and profit yields increase significantly. We refer to our vertical farming as 'vertical plus,' because while there are minor similarities with conventional vertical farming, the system we will use is a remarkable advance in farming," said Linda Sampson, Marapharm CEO.
"In addition to increased yields and quality, the vertical plus system saves us a lot of money which otherwise would have been spent on construction. Building plans are being modified to accommodate vertical plus growing for the two 5000' square foot starter buildings and the entire 360,000 square foot building all on the 7 acres owned by Marapharm, located in Apex Industrial Park, Las Vegas, Nevada. Construction drawings of the 30,000 square foot building located in Washington State are also being modified and changes will include the deletion of a proposed mezzanine; all mezzanines in all buildings will be eliminated. And there will be no delays in construction or growing with the addition of the vertical plus farming," added Sampson.
ABOUT MARAPHARM VENTURES INC.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV, and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com), and Sedar website (www.sedar.com) under the profile for Marapharm Ventures Inc.
FOR FURTHER INFORMATION:
Neither the CSE, the FSE, nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE, nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate," "continue," "estimate," "expect," "may," "will," "project," "should," "believe," and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
SOURCE: Marapharm Ventures Inc.